Skip to content
OpenCapital
Get started

AbCellera Biologics Inc. ABCL Cash & Equivalents

Cash & Equivalents at other companies

Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
$124.85M-41.4%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$665.18M+30.6%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$248.47M+152%
Zymeworks logo
ZymeworksZYME
$244.28M+221%
Precigen logo
PrecigenPGEN
$7.48M+23.5%
ADMA Biologics logo
ADMA BiologicsADMA
$138.15M+92.9%

Other financials

Income statement

See full
Revenue$8.3M+96.3%
Operating income-$57.5M+8.2%
Net income-$43.2M+5.4%
EPS (diluted)-$0.14+6.7%

Balance sheet

See full
Total debt$140.2M+107%
Total equity$938.1M-8.3%
Total assets$1.3B-2.8%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$3.8M-64.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.72B+59.2%
Enterprise value$1.76B+100.0%
P/S21.7×-25.0×

Profitability

See full
Operating margin-267.6%-120pp
Net margin-181.7%-77.9pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-14.7%-0.8pp
Debt / equity0.1×+0.1×
Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbCellera Biologics Inc.'s cash & equivalents?
AbCellera Biologics Inc. (ABCL) reported cash & equivalents of $102.06M in Q1 2026.
How has AbCellera Biologics Inc.'s cash & equivalents changed year-over-year?
AbCellera Biologics Inc.'s cash & equivalents decreased by 44.6% year-over-year, from $184.27M to $102.06M.
What is the long-term trend for AbCellera Biologics Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), AbCellera Biologics Inc.'s cash & equivalents has grown at a -26.4% compound annual growth rate (CAGR), from $594.12M to $128.51M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.